Takeda Pharmaceutical Company Limited【JP:4502】Stock Price

Takeda Pharmaceutical Company Limited is a global pharmaceutical company primarily engaged in the pharmaceutical business. The company focuses on six key business areas: gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience (neuropsychiatric diseases). It conducts research, development, manufacturing, and sales in these fields to provide innovative pharmaceuticals.

In research and development, the company prioritizes three therapeutic areas: gastrointestinal and inflammatory diseases, neuroscience, and oncology. It also invests in plasma-derived therapies and has built a robust and diverse drug discovery pipeline. Through these efforts, the company aims to address significant unmet medical needs for diseases that currently lack established effective treatments.

Takeda Pharmaceutical Company Limited promotes the use of data, digital technology, and innovation to improve operational efficiency and drive innovation. This enables the company to deliver high-quality pharmaceuticals to patients and communities rapidly while enhancing value creation for stakeholders.

In Japan, Takeda Pharmaceutical Company Limited conducts research and development, manufacturing, and sales. Overseas, subsidiaries and affiliated companies in various countries handle these functions. In the United States, major subsidiaries include Takeda Pharmaceuticals U.S.A., Inc. and Baxalta US Inc. In Europe and Canada, Takeda Pharmaceuticals International AG and Takeda GmbH operate. In other regions, Takeda (China) International Trading Co., Ltd. and Takeda Distribuidora Ltda. serve as major subsidiaries.

Takeda Pharmaceutical Company Limited, as a global pharmaceutical company, focuses on six key therapeutic areas: gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. Through research, development, manufacturing, and sales in these areas, the company continues to deliver innovative medicines.

The company is advancing research and development to address unmet medical needs, particularly in three priority disease areas: gastrointestinal and inflammatory diseases, neuroscience, and oncology. This aims to create medicines with the potential to fundamentally improve patients' lives.

Takeda Pharmaceutical is promoting the use of data, digital technology, and innovation to improve operational efficiency and drive innovation. This enables the company to deliver high-quality medicines to patients and communities more rapidly while strengthening value creation for stakeholders.

The company is strengthening its late-stage development pipeline to achieve sustainable growth beyond 2030. Through the discovery and development of innovative therapies, it aims to create value for society and stakeholders.

Additionally, Takeda Pharmaceutical prioritizes environmental responsibility and promotes sustainable business operations. The company is advancing the use of clean energy and reducing greenhouse gas emissions to conduct environmentally conscious business activities.